- Home
- NINE vs ALXO Comparison
NINE vs ALXO Comparison
Compare NINE & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NINE
- ALXO
- Stock Information
- Founded
- NINE 2011
- ALXO 2015
- Country
- NINE United States
- ALXO United States
- Employees
- NINE N/A
- ALXO N/A
- Industry
- NINE Oilfield Services/Equipment
- ALXO Biotechnology: Pharmaceutical Preparations
- Sector
- NINE Energy
- ALXO Health Care
- Exchange
- NINE Nasdaq
- ALXO Nasdaq
- Market Cap
- NINE 23.8M
- ALXO 24.0M
- IPO Year
- NINE 2018
- ALXO 2020
- Fundamental
- Price
- NINE $0.61
- ALXO $0.61
- Analyst Decision
- NINE
- ALXO Strong Buy
- Analyst Count
- NINE 0
- ALXO 6
- Target Price
- NINE N/A
- ALXO $3.30
- AVG Volume (30 Days)
- NINE 694.5K
- ALXO 569.7K
- Earning Date
- NINE 08-05-2025
- ALXO 08-12-2025
- Dividend Yield
- NINE N/A
- ALXO N/A
- EPS Growth
- NINE N/A
- ALXO N/A
- EPS
- NINE N/A
- ALXO N/A
- Revenue
- NINE $577,300,000.00
- ALXO N/A
- Revenue This Year
- NINE $3.64
- ALXO N/A
- Revenue Next Year
- NINE N/A
- ALXO N/A
- P/E Ratio
- NINE N/A
- ALXO N/A
- Revenue Growth
- NINE 3.23
- ALXO N/A
- 52 Week Low
- NINE $0.44
- ALXO $0.40
- 52 Week High
- NINE $1.87
- ALXO $2.79
- Technical
- Relative Strength Index (RSI)
- NINE 34.42
- ALXO 55.55
- Support Level
- NINE $0.68
- ALXO $0.44
- Resistance Level
- NINE $0.74
- ALXO $0.64
- Average True Range (ATR)
- NINE 0.05
- ALXO 0.06
- MACD
- NINE -0.02
- ALXO 0.01
- Stochastic Oscillator
- NINE 7.22
- ALXO 56.04
About NINE Nine Energy Service Inc.
Nine Energy Service Inc is a North American onshore completion and production services provider. It targets unconventional oil and gas resource development. It operates in one segment, Completion Solutions. The Completion Solutions segment offers cementing services; completion tools, including liner hangers and accessories, frac sleeves, fully composite frac plugs, and specialty open hole float equipment and centralizers and other services. It operates in the U.S, Canada, and other countries where majority of the revenue is generated from the United States.
About ALXO ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.